ViewRay, Inc. has launched a multicenter prospective clinical trial for locally advanced unresectable pancreatic cancer using MRIdian, the only FDA-cleared MRI-guided radiation therapy system. This study is the first initiative of ViewRay’s Clinical Cooperative Think Tank (C2T2), a group of MRIdian clinical users focused on evidence gathering to support MR-guided radiation therapy.
At the inaugural meeting of the C2T2 on September 23, 2017, participants formalized the group’s first key initiative – a multicenter, prospective, single-arm clinical trial focused on locally advanced unresectable pancreatic cancer. Pancreatic cancer presents considerable radiation targeting challenges given the known limitations of conventional CT image guidance. The novel abilities provided by live MR guidance combined with daily online treatment adaptation have potentially enabled a new approach in pancreatic cancer therapy. Through this
One particular impetus for the trial was compelling early results presented as part of the scientific sessions at the American Society for Radiation Oncology (ASTRO) annual meeting. The poster, titled “Higher Maximum Biologic Effective Dose Utilizing Adaptive MRI Guided Radiation Therapy Improves Survival of Inoperable Pancreatic Cancer Patients”, provided a retrospective review of 42 locally-advanced pancreatic cancer patients treated at four institutions (Washington University, UCLA, University of Wisconsin, and VUmc). The study found that stereotactic dosing regimens guided by MR imaging and daily online adaptation had led to significantly prolonged patient survival and resulted in favorably low toxicity.
“Based on compelling early evidence on the use of MRIdian to treat locally advanced pancreatic cancer, we are eager to further explore the system’s capabilities and associated toxicity, local
A video of Dr. Parikh discussing the multiinstitutional poster in ViewRay’s ASTRO booth is available at http://www.viewray.com/ASTRO_2017.
As part of ASTRO’s Scientific Sessions, an additional presentation of pancreatic cancer outcomes from UCLA will be delivered. The presentation titled, “Outcomes Utilizing MRI-guided and Real-Time Adaptive Pancreas Stereotactic Body Radiotherapy (SBRT)” will be given on Wednesday, September 27 at 2:40 p.m. PT in room 30 D/E.
ViewRay’s C2T2, the consortium initiating the trial, comprises clinicians from leading institutions around the world including:
- Dana-Farber/Brigham and Women's Cancer Center in Boston
- Henry Ford Cancer Institute, Detroit
- Institut du Cancer de Montpellier, France
- Institut Paoli Calmettes, Marseille, France
- Loyola Center for Cancer Care and Research at Palos Health South Campus in Illinois
- Moffitt Cancer Center in Tampa, Florida
- Miami Cancer Institute, Baptist Health South Florida
- National Cancer Center (NCC) in Tokyo, Japan
- NewYork-Presbyterian Hospital
- Orlando Health UF Health Cancer Center
- Policlinico Agostino Gemelli, Universita Cattolica del Sacro Cuore, Gemelli ART in Rome, Italy
- Seoul National University Hospital (SNUH) in Seoul, South Korea
- Sylvester Comprehensive Cancer Center, UHealth - University of Miami Health System
- University Clinic Heidelberg, German Research Foundation (DFG)
- University of Wisconsin Carbone Cancer Center in Madison
- VU University Medical Center in Amsterdam, Netherlands
- Washington University and Siteman Cancer Center at Barnes-Jewish Hospital, St. LouisBack To Top
ASTRO 2017: ViewRay launches clinical trial following early pancreatic cancer data with MRIdian system . Appl Rad Oncol.